Table 1.
Patient baseline characteristics
| N = 38 | |
|---|---|
| Age, years, n (%) | |
| Overall, years, median (range) | 74 (43–86) |
| > 75 | 11 (28.9) |
| 65–75 | 20 (52.6) |
| < 65 | 7 (18.4) |
| Sex, n (%) | |
| Male | 13 (34.2) |
| Female | 25 (65.8) |
| ECOG performance status, n (%) | |
| 0 | 14 (36.8) |
| 1 | 24 (63.2) |
| Number of prior chemotherapy regimens, n (%) | |
| 1 | 23 (60.5) |
| 2 | 15 (39.5) |
| Time-to-enrollment since the initiation of first-line therapy, n* (%) | |
| < 12 months | 7 (18.4) |
| ≥ 12 months | 16 (42.1) |
| Prior HDC/ASCT, n (%) | |
| Present | 6 (15.8) |
| Absent | 32 (84.2) |
| Ann Arbor clinical stage, n (%) | |
| I–II | 13 (34.2) |
| III | 6 (15.8) |
| IV | 19 (50.0) |
| Tumor size | |
| ≥ 5 cm, n (%) | 10 (26.3) |
| Cell-of-origin category by gene expression profiling, n (%) | |
| • GCB | 6 (15.8) |
| • ABC | 9 (23.7) |
| • Unclassified | 5 (13.2) |
| Hans algorithm, n (%) | |
| • GCB | 12 (31.6) |
| • Non-GCB | 23 (60.5) |
| International prognostic index risk category, n (%) | |
| Low + low intermediate | 29 (76.3) |
| High intermediate + high | 9 (23.7) |
*Includes eligible patients who received 1 regimen; other patients who received 2 regimens or ASCT were not included
N total number of patients, n number of patients, ECOG Eastern Cooperative Oncology Group, HDC/ASCT high-dose chemotherapy/autologous stem cell transplantation, GCB germinal center B-cell-like, ABC activated B-cell-like